Adimab will be responsible for the discovery of new therapeutic antibodies for Ono’s multiple targets. It will also create bispecific antibody product candidates.
Ono will assess and develop those candidates at the pre-clinical and clinical stages.
The company will have the option to receive exclusive rights for the global development, manufacturing and commercialisation of the candidates generated through the partnership.
Ono discovery and research senior executive officer and executive director Dr Toichi Takino stated: “We are actively working to create biologics like antibodies in order to address unmet medical needs for a wide range of diseases, including cancers.
“We are very pleased to collaborate with Adimab this time in the oncology area and expect that their multi-specific antibody engineering technologies will create potential novel bispecific antibody candidates.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Adimab will receive an upfront payment, research and development funding, and success-based milestones from Ono on research, clinical development and regulatory progress, and tiered royalties based on net sales.
Adimab chief business officer Guy Van Meter stated: “We are very pleased to be able to partner with Ono Pharmaceuticals based on our technology in antibody discovery and bispecific antibody generation. Adimab has more than 105 partners across the world, and we are thrilled to add Ono to our partners’ list.”